Key points are not available for this paper at this time.
The evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (Grade Group 2 or higher GG2+). The use of laboratory biomarkers, prostate MRI, and biopsy techniques described herein may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.
Building similarity graph...
Analyzing shared references across papers
Loading...
John T. Wei
Kunming University of Science and Technology
Daniel A. Barocas
Vanderbilt University Medical Center
Sigrid Carlsson
Memorial Sloan Kettering Cancer Center
The Journal of Urology
University of Washington
University of Michigan
Johns Hopkins University
Building similarity graph...
Analyzing shared references across papers
Loading...
Wei et al. (Tue,) studied this question.
synapsesocial.com/papers/69d7f7993eff0c9dfaae2e12 — DOI: https://doi.org/10.1097/ju.0000000000003492